Dashboard
1
Poor Management Efficiency with a low ROE of 2.89%
- The company has been able to generate a Return on Equity (avg) of 2.89% signifying low profitability per unit of shareholders funds
- NO KEY NEGATIVE TRIGGERS
2
Risky -
3
Consistent Underperformance against the benchmark over the last 3 years
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-88.39%
0%
-88.39%
6 Months
-88.76%
0%
-88.76%
1 Year
-96.73%
0%
-96.73%
2 Years
-96.48%
0%
-96.48%
3 Years
-97.49%
0%
-97.49%
4 Years
-96.69%
0%
-96.69%
5 Years
-92.35%
0%
-92.35%
Futura Medical Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
54.84%
EBIT Growth (5y)
2.23%
EBIT to Interest (avg)
-5.70
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.74
Sales to Capital Employed (avg)
1.20
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
9.43%
ROE (avg)
2.89%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.69
EV to EBIT
-1.18
EV to EBITDA
-1.20
EV to Capital Employed
-7.55
EV to Sales
0.95
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-206.60%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
3.10
0.00
Operating Profit (PBDIT) excl Other Income
-7.00
-6.70
-4.48%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-6.50
-5.80
-12.07%
Operating Profit Margin (Excl OI)
-2,245.70%
0.00%
-224.57%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -12.07% vs -16.00% in Dec 2022
About Futura Medical Plc 
Futura Medical Plc
Pharmaceuticals & Biotechnology
Futura Medical plc is a United Kingdom-based pharmaceutical company that develops products for consumer healthcare. The Company is engaged in the research and development of pharmaceutical drugs and medical devices and the commercial exploitation. It is also engaged in transdermal delivery and has developed a transdermal technology, DermaSys for the absorption of active molecules through the skin. It specializes in sexual health and pain relief, and has approximately five products in its development pipeline, which include CSD500, MED2002, TPR100, TIB200 and SPR300. Its CSD500 product incorporates an erectogenic gel (known as Zanifil gel) to help men maintain a firmer erection during intercourse whilst wearing a condom. Its MED2002 is a gel applied directly to the penis for the treatment of male erectile dysfunction (ED). The Company's TPR100 is a gel to provide pain relief. Its SPR300 is a gel, which combines methyl salicylate and menthol with the DermaSys delivery system.
Company Coordinates 
Company Details
Unit 40, Surrey Technology Centre, Occam Road GUILDFORD None : GU2 7YG
Registrar Details






